[A review on the development of Kallikrein (Kallidinogenase)].

This article briefly summarizes the historical events particularly these in Japan, in the kallikrein-kinin research and progress of the development of kallidinogenase (INN), enzyme with circulatory action. In 1926, E. K. Frey observed a drop in blood pressure in dogs following intravenous injection of the urine of human and other mammals into dogs. Intensive research showed that the urine contained a high-molecular active substance which dilated the peripheral arterial vessels. The substance was later called kallikrein after the Greek synonym for pancreas, as it occurred there at such a high concentration (Kraut et al., 1930) that this gland was thought to be its cite of origin. In 1930, kallikrein was commercially available as Padutin from Bayer, Germany. The product was introduced into Japan a few years later under the trade name of Kallikrein and was used for the treatment of circulatory disorders even during the Second World War. Kallikrein was again imported by Yoshitomi Pharmaceutical Industries, Ltd. in 1952. However, Kallikrein introduced after the War did not contain substance derived from the urine but from porcine pancreatic kallikrein as the active ingredient. It grew rapidly with its active promotion of the product in such fields as internal medicine, ophthalmology, otology etc. Domestic manufacturers increasingly entered this market and the number of the manufacturing license holders of similar products reached 26 in 1975 when kallidinogenase preparations were designated to undergo drug re-evaluation by the health authorities. Since June 1988 when the re-evaluation for kallidinogenase preparations was completed, all the relevant manufacturers have supplied new formulations containing higher quality substances and labeling their potencies expressed in International Units based on the kallidinogenase reference standards which had since been established.